MoonLake Immunotherapeutics MLTX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $202.86M+79.9% | $112.77M+255% | $31.8M-24.7% | $42.25M— | ||
| $244.84M+71.1% | $143.09M+164% | $54.12M-16.8% | $65.06M— | ||
| $611K+117% | $282K+200% | $94K+158% | $36.37K— | ||
| -$227.32M-91.1% | -$118.94M-230% | -$36.01M+34.8% | -$55.22M+40.4% | ||
| -$242.22M-70.9% | -$141.71M-164% | -$53.75M-4.0% | -$51.67M— | ||
| -$244.84M-71.1% | -$143.09M-164% | -$54.12M-4.4% | -$51.83M-1,034% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is MoonLake Immunotherapeutics profitable?
- MoonLake Immunotherapeutics is not currently profitable: it reported a net loss of $257.1M over the trailing twelve months.
- What is MoonLake Immunotherapeutics's earnings per share?
- MoonLake Immunotherapeutics's diluted EPS over the trailing twelve months is $-3.87.
- Where does MoonLake Immunotherapeutics's income statement data come from?
- Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.